Pharmaceutical News

RSS

ECR announces availability of Zolpimist Oral Spray in the U.S.

ECR Pharmaceuticals Co., Inc., a subsidiary of Hi-Tech Pharmacal Co., Inc. announced the immediate availability of Zolpimist Oral Spray, a novel delivery system of the most widely prescribed sleep aid in the US, zolpidem tartrate.

4 Feb 2011

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.

4 Feb 2011

Scientists analyze relationship between drug abuse, recognition of basic emotions

University of Granada scientists have been the first to analyze the relation between drug abuse and recognition of basic emotions by drug-abusers.

4 Feb 2011

Study finds increased prescription drug abuse among teens

Illicit drugs like marijuana, cocaine and heroin have always been a parent's nightmare. But perfectly legal and easily accessible prescription medications are now the recreational drugs of choice for many teenagers, prompting physicians at Johns Hopkins Children's Center to urge pediatricians to screen specifically for their abuse during routine visits.

4 Feb 2011

AHF urges all AIDS drug manufacturers to reduce medication cost by 20%

As part of its ongoing advocacy to lower drug prices and increase access to lifesaving medications AIDS Healthcare Foundation, the largest global AIDS organization, today urged all AIDS drug manufacturers to reduce the cost of their medications by 20% for cash-strapped state.

4 Feb 2011

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Tacere Therapeutics, an RNA interference (RNAi)-based therapeutics company, announced today that it has reacquired the development and commercialization rights to its Hepatitis C Virus compounds throughout Asia from its strategic partner, Tokyo-based Oncolys BioPharma Inc.

4 Feb 2011

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

AMRI announced today that it has received approval from the Italian Medicines Agency (AIFA) for its facility in Burlington, MA to manufacture the commercial drug product octreotide for a customer in the European Union (EU).

4 Feb 2011

MedAssurant, UNC to assess relationship between insulin and cancer development

MedAssurant, a leading provider of data-driven healthcare solutions, today announced the initiation of a joint study with the University of North Carolina to assess the relationship between the use of long-acting insulin to treat diabetes and the development of cancer.

4 Feb 2011

Sodium Thiosulfate Injections recalled

American Regent is conducting a nationwide voluntary recall.

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

FDA approves Hospira's topotecan for SCLC

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United States.

3 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.

3 Feb 2011

Public health experts: Improved community engagement needed to prevent pandemic spread

In the current issue of Journal of Public Health Management and Practice, public health experts assert that improved community engagement is needed to prevent the spread of pandemics.

3 Feb 2011

Ta`am Teva Altman, Probi sign agreement to launch dietary supplement for gut health

Probi has signed an agreement giving Ta`am Teva Altman rights to launch Probi's dietary supplement for gut health based on Lp299v™ in Israel. The launch is planned to take place in the second quarter of 2011.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

New study highlights black box warning inconsistencies on drug's label

A new study highlights inconsistencies in black box warnings - medication-related safety warnings on a drug's label - and argues for a more transparent and systematic approach to ensure these warnings are consistent across all drugs within a same category, and any additions to warnings, on the back of a drug withdrawal for example, are done within a reasonable and uniform time period.

3 Feb 2011

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

3 Feb 2011

Proper diagnosis and antibiotic treatment are the best way to prevent Lyme arthritis

Early, correct diagnosis is the best way to prevent the development of Lyme arthritis in individuals with the tick-borne illness, according to a paper published in the Journal of the American Academy of Orthopaedic Surgeons. In patients who do develop the condition, most cases can be treated successfully with antibiotics, the review found.

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011